Advertisement
Advertisement

TSHA

TSHA logo

Taysha Gene Therapies, Inc. Common Stock

6.68
USD
Sponsored
+0.31
+4.87%
Aug 11, 16:00 UTC -4
Closed
exchange

After-Market

6.33

-0.35
-5.27%

Taysha Gene Therapies, Inc. Common Stock Profile

About

Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.

Info & Links

CEO

Sean Nolan

Headquarters

3000 Pegasus Park Dr. Ste 1430
DALLAS, TX 75247, UNITED STATES

Industry

Medical Generic Drugs

Sector

Medical

Website

www.tayshagtx.com

Auditor

Deloitte & Touche LLP

Share holders

34

Employees

99

Taysha Gene Therapies, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

1.82B

Enterprise Value

1.59B

Enterprise Value/EBITDA(ttm)

-12.10

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

232.78

Price to Book(mrq)

8.89

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

50.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

-465.34%

Return on Equity(ttm)

-56.07%

Return on Invested Capital(ttm)

-47.04%

Return on Assets(ttm)

-40.16%

Income Statement

Revenue(ttm)

7.47M

Revenue Per Share(ttm)

0.03

Gross Profit(ttm)

7.47M

EBITDA(ttm)3

-131.41M

Net Income Available to Common(ttm)

-129.88M

Diluted EPS(ttm)

-0.38

Share Statistics

Beta (5Y Monthly)

1.22

52-Week Change

145.59%

S&P 500 52-Week Change

19.90%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

287.36M

Dividend Yield

0.00%

Float4

277.36M

% Held by Insiders

3.48%

% Held by Institutions

77.70%

Balance Sheet

Total Cash(mrq)

277.02M

Total Cash Per Share(mrq)

0.96

Total Debt(mrq)

48.96M

Total Debt/Equity(mrq)

23.10%

Current Ratio(mrq)

14.04%

Quick Ratio(mrq)

14.04%

Book Value Per Share(mrq)

0.74

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.11

Free Cash Flow(ytd)

-40.90M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement